Many transfusion centers nationwide look to adjust to the shortage of Sotrovimab, the only monoclonal antibody treatment shown effective against the Omicron variant.

What You Need To Know

  • Transfusion centers nationwide report shortage of  Sotrovimab

  • U.S. has ordered $1 billion worth of the monoclonal antibody treatment

  • Monoclonal antibodies play a vital role in preventing hospitalization or death

Monoclonal antibodies have played a vital role in helping to prevent hospitalization or death.

Last month, the U.S. announced it ordered $1 billion worth of Sotrovima, but in the meantime health departments across the country will need to make do with the medications they currently have.

“However, a very small supply has been sent out to the different infusion therapies at this point,” Dr. Karenna Senors with True Health said. “So, the recommendation is to use what we have because at least that will help some.”

While Omicron has been less severe compared to Delta, medical experts warn it can still be dangerous for the unvaccinated.

“The unvaccinated can still have mild to severe. I expect the hospital rates to go up,” Dr. Senors said. "I expect the number of people admitted to the hospital to go up again. Especially if we’re not getting the newer medication. The Sotrovimab will definitely help.”

Doctor Senors said so far this month, True Health’s Infusion  center has performed 71 infusions that’s 50 more compared to last month.